Richard Nathan, DO
Infectious Disease · Idaho Falls, IDNPI 1942229570
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.8%), food and beverage and education — rather than concentrated in one kind of arrangement. 14 manufacturers reported payments, led by Pfizer at 40.8% of the total. Reporting peaked in 2019 at $3,726 and has fallen 95.4% since, to $170 in 2025. Among infectious disease clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 111 payments — averaging $45.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$2K
- Sanofi Pasteur Inc.$1K
- AbbVie$544
- Melinta Therapeutics, LLC$240
- Merck$189
- AstraZeneca$143
- plus $418 from 8 others
Across 307 payments — averaging $4606.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bavarian Nordic A/s$374K
- Sanofi Pasteur Inc.$366K
- Modernatx, Inc.$228K
- Novartis$162K
- Pfizer$84K
- BD$70K
- plus $130K from 4 others
What the payments were for
- Travel & lodging$2,94158%
- Food & beverage$2,01040%
- Education$1363%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 5 | $2,073 |
| Sanofi Pasteur Inc. | 12 | $1,479 |
| AbbVie(2 entities) | 51 | $544 |
| Melinta Therapeutics, LLC | 11 | $240 |
| Merck | 11 | $189 |
| AstraZeneca | 3 | $143 |
| Astellas Pharma US Inc | 5 | $112 |
| Insmed, Inc. | 2 | $80 |
| Tetraphase Pharmaceuticals, Inc. | 2 | $56 |
| Ferring Pharmaceuticals Inc. | 3 | $51 |
| La Jolla Pharmaceutical Company | 2 | $43 |
| Gilead | 2 | $36 |
| Shionogi Inc | 1 | $26 |
| Amgen | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NO PRODUCT DISCUSSED$1,306
How this compares
$5,086 in reported general payments places this provider in the 95th percentile of 29 infectious disease providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Daptomycin | 54 | $25,805 |
| ErtapenemErtapenem Sodium | 25 | $13,847 |
| Sodium Chloride0.9 % Sodium Chloride | 47 | $1,411 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 52 | $1,168 |
| Cefdinir | 11 | $886 |
| Clindamycin Hcl | 30 | $532 |
| Fluconazole | 38 | $440 |
| Cephalexin | 33 | $424 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 36 | $405 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 20 | $329 |
| Cefadroxil | 14 | $278 |
| Doxycycline Hyclate | 18 | $158 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Idaho Falls
- John BagwellIdaho Falls$149
- Martha BuitragoIdaho Falls$139
- David PomboIdaho Falls$47
- Sean Tristan CookCoeur D Alene$32K
- Sky BlueBoise$2K
- Thomas CoffmanBoise$838
- Sarah ShewayishBoise$769
- Quentin DoperalskiBoise$516
- John HammerBoise$389
- Sharon OsterBoise$327
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.